Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients

Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy

Multiple myeloma science from EHA 2019

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone

HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma

The changing landscape of AML

Using bioinformatics and genomics to treat AML

Blinatumomab for relapsed/refractory Burkitt's lymphoma

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

Chemoimmunotherapy or BTK inhibition for patients with CLL